Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy.

The prognosis of patients with hepatocellular carcinoma (HCC) undergoing hepatectomy is unsatisfactory, especially for those with microvascular invasion (MVI). This study aimed to determine the impact of adjuvant transcatheter arterial chemoembolization (TACE) and Lenvatinib on the prognosis of patients with HCC and MVI after hepatectomy. Patients diagnosed with HCC and MVI were reviewed, and stratified into four groups according to adjuvant TACE and/or Lenvatinib. Multivariate Cox regression analyses are used to determine independent risk factors. 346 patients were included, and divided into four groups (Group I, TACE+ Lenvatinib; Group II, Lenvatinib; Group III, TACE; Group IV, without adjuvant therapy). Multivariable analysis showed that compared to Group IV, Group I had the best effect on improving the overall survival (OS, HR 0.321, 95%CI 0.099–0.406, P = 0.001) and recurrence-free survival (RFS, HR 0.319, 95%CI 0.129–0.372, P = 0.001). Additionally, compared with Group II or Group III, Group I also can significantly improve the OS and RFS. There is no significant difference between Group II and Group III in OS and RFS. The combination of TACE and Lenvatinib should be considered for anti-recurrence therapy for patients with HCC and MVI after hepatectomy. • The results showed that for high-risk patients, adjuvant TACE combined with Lenvatinib is better than single-agent. • Adjuvant TACE combined with Lenvatinib which can effectively reduce recurrence and improve long-term prognosis. • There was no significant survival difference between TACE and Lenvatinib. [ABSTRACT FROM AUTHOR]